Ryan White Care Hepatitis C & B Language
NATAP Webinars
HIV Treatment Strategies & Prevention CROI 2024
Friday, April 5th, 2024 - 1:00pm
Click To Register:
HIV Treatment Strategies & Prevention CROI 2024
View all archived NATAP webinars here
Current HIV Articles and News Updates
HIV
Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study
- (03/14/24)
 
CROI:
Phone calls for PrEP persistence in Kenyan women in postabortal care: a cluster randomized trial.
- Mark Mascolini (03/12/24)
 
CROI:
PrEP Non-Persistence and New HIV Diagnoses: A Real-World Analysis of >120,000 People Prescribed PrEP
- (03/12/24)
 
CROI:
Safety of dapivirine vaginal ring and oral PrEP for HIV prevention in the second trimester.
- Mark Mascolini (03/12/24)
 
CROI:
CHANGES IN HIV PREP AWARENESS & USE AMONG PWID IN 19 U.S. CITIES, 2018 & 2022 ....very low PrEP use
- (03/12/24)
 
CROI:
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: HPTN 083
- (03/12/24)
 
CROI:
Healthcare Staff Acceptability and Feasibility of Telehealth Delivery of Cabotegravir for PrEP
- (03/12/24)
 
CROI:
Interest in Long-Acting Injectable PrEP Among Transgender Women in the United States
- (03/12/24)
 
CROI:
Real-World Use of Cabotegravir Long-Acting for Preexposure Prophylaxis: Trio Health Cohort
- (03/12/24)
 
CROI:
Preexposure Prophylaxis With Cabotegravir Long-Acting Injectable in the OPERA Cohort
- (03/12/24)
 
More HIV Articles...
Hepatitis D
HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines
 
AASLD:
Epidemiological and Clinical Characteristics of HBV and HDV Co-infected Patients Followed by the Canadian HBV Network
- (11/20/23)
 
More Hep D Articles...
 
Aging & Perinatally HIV Infected
 
CROI:
CSF ART Exposure, Population Pharmacokinetic Approaches to Standardize Antiviral Exposure in the Cerebrospinal Fluid
- (03/16/24)
 
CROI:
No neurocognitive benefit of immediate vs delayed tesamorelin in virally suppressed people with HIV
- (03/16/24)
 
CROI:
Socio-Demographics Were Stronger Classifiers of Cognitive Profiles Than Neuroimaging in HIV
- (03/16/24)
 
CROI:
EXTRA-CVD: A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention
- (03/16/24)
 
CROI:
Treatment of Prehypertension in People Living With HIV: A Randomized Controlled Trial
- (03/16/24)
 
CROI:
Pitavastatin Has No Effect on Long-Term, Objective Physical Function in REPRIEVE
- (03/16/24)
 
CROI:
Performance of the ACC/AHA Pooled Cohort Equations or Risk Prediction in the Global REPRIEVE Trial
- (03/16/24)
 
CROI:
Factors Contributing to Risk of Major Adverse Cardiovascular Events among People with HIV in REPRIEVE
- (03/16/24)
 
CROI:
Pitavastatin Reduces Non-Calcified Plaque via Pro-Collagen PCOLCE Independently of LDL in REPRIEVE
- (03/16/24)
 
CROI:
Aging at CROI 2024
- (03/16/24)
 
CROI:
Semaglutide at CROI 2024
- (03/16/24)
 
CROI:
Relating Pitavastatin Effects on Inflammatory Biomarkers to Plaque Changes in REPRIEVE
- (03/16/24)
 
CROI:
Carotid Inflammation on FDG-PET Is Associated With Lower Cognitive Function in Treated HIV Infection
- (03/16/24)
 
More Aging & HIV Articles...
 
Covid
 
CROI:
Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study
- (03/15/24)
 
CROI:
Hospital and Death Rate Almost Twice Higher After SARS-CoV-2 in Unvaccinated
- Mark Mascolini (03/11/24)
 
CROI:
COVID Incidence and Severity in Persons with Reinfection vs Post-vaccination Breakthrough Infection....>65, comorbidities protected more
- (03/11/24)
 
More Covid Articles...
Current Hepatitis C and B Articles
Hepatitis C
CROI:
Preclinical Pharmacokinetic Assessment of a Hepatitis C Virus Long-Acting Injectable Formulation
- (03/15/24)
 
CROI:
Leading Causes of Death Among People With HIV in the US, 2001-2019...4x greater death risk than gen. pop., cancer & heart disease, HIV leading causes of death, Blacks have higher death rates
- (03/13/24)
 
CROI:
Peripartum Linkage to Care in Hepatitis C: Maternal Treatment and Infant Testing
- (03/07/24)
 
Hepatitis C Virus Elimination Programs in Louisiana and Washington: Importance of Screening and Surveillance Systems
- (02/26/24)
 
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions
- (02/26/24)
 
Eliminating viral hepatitis: no room for complacency; lack of political will
- (02/26/24)
 
'not very good' Progress towards global elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update
- (02/26/24)
 
More Hep C Articles...
Hepatitis B
HBV Patient Declaration of Rights
-
 
CROI:
HepB-CpG vaccine is superior to HepB-alum in people with HIV and prior vaccine non-response (A5379)
- (03/15/24)
 
CROI:
Factors Associated With HBV Response to B/F/TAF Versus DTG + F/TDF at Week 96 in People With HIV-1 and HBV
- (03/15/24)
 
Moving beyond the guidelines to improve detection of viral hepatitis (HBV) and linkage to care
- (02/07/23)
 
HBV functional cure finding-Cytosine base editing inhibits Hepatitis B Virus replication and reduces HBsAg expression in vitro and in vivo
- (01/08/23)
 
AASLD:
Higher-Than-Expected Isolated Hep B Core Antibodies in Philadelphia Screening
- Mark Mascolini (11/29/23)
 
AASLD:
Re-vaccination against hepatitis B in previous non-responders following hepatitis C eradication
- Mark Mascolini (11/29/23)
 
AASLD:
Metabolomic profiling to predict histologic progression of liver fibrosis in patients with HIV and HBV coinfection: 20% have fibrosis progression in 3 years
- Mark Mascolini (11/29/23)
 
AASLD:
HBV Vaccine Improves Survival With Liver Diseases Beyond HBV Infection
- Mark Mascolini - (11/29/23)
 
More Hep B Articles...
 
Fatty Liver, NAFLD, NASH
 
CROI:
Effects of Semaglutide on Muscle Structure and Function in the SLIM Liver Study
- (03/12/24)
 
CROI:
Semaglutide Lowers Some Inflammation Markers in HIV Lipohypertrophy
- Mark Mascolini (03/12/24)
 
CROI:
Low-Dose Semaglutide Cuts Weight, Triglycerides, and Glucose in HIV MASLD Group
- Mark Mascolini (03/12/24)
 
CROI:
Race/Ethnicity and Risk of NAFLD and Clinically Significant Fibrosis in Persons Living with HIV
- (03/12/24)
 
CROI:
NAFLD and Advanced Fibrosis Are Common in Adults With HIV and Associated With Unique Histology
- (03/12/24)
 
More Fatty Liver Articles...
Check Out Our Special NATAP Features
List not necessarily listed here in order of date being held.
22 February 2024 - 23 February 2024 Nairobi Kenya
https://academicmedicaleducation.com/meeting/african-workshop-hiv-women-2024
May 2-4, 2024 Atlanta, GA
https://acthiv.org/acthiv-2024-program/
https://ddw.org/
https://easl.eu/event/easl-congress-2024/
https://asm.org/Events/ASM-Microbe/Home
Munich, Germany, and virtually from 22 to 26 July 2024.
Pre-conferences will be held on 20 and 21 July.
https://www.iasociety.org/conferences/aids2024
Conference on Liver Disease in Africa (COLDA) 2024
19 September 2024 - 21 September 2024 Egypt
https://academicmedicaleducation.com/meeting/conference-liver-disease-africa-colda-2024
18 September 2024 - 20 September 2024 Liverpool, United Kingdom
https://academicmedicaleducation.com/meeting/international-workshop-clinical-pharmacology-hiv-hepatitis-and-other-antiviral-drugs-2024
https://www.iasociety.org/conferences/hivr4p2024/registration
https://idweek.org/#
24 October 2024 - 25 October 2024 United States
Washington DC, United States
https://academicmedicaleducation.com/meeting/international-workshop-hiv-aging-2024
10-13 November 2024
https://hivglasgow.org/
San Diego, California
https://www.aasld.org/liver-meeting-tlm-2024
https://informedhorizonseducation.com/hiv-respidart-2024